New combo aims to reboot immunotherapy in resistant cancers
NCT ID NCT04219254
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new drug called BI-1206, given alongside the immunotherapy pembrolizumab, in adults with advanced solid tumors that have stopped responding to prior anti-PD-1/PD-L1 treatment. The study aims to find the safest dose and check for early signs of tumor shrinkage. About 197 participants will receive the combination intravenously or under the skin every three weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI-1206 (a monoclonal antibody) combined with pembrolizumab
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced solid tumors who have stopped responding to standard immunotherapy.
What could go wrong
This is an early-phase trial (phase 1/2a) with a small number of participants. The drug may not work or could cause serious side effects. It is not yet proven to be safe or effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centrul de Oncologie SF Nectarie SRL
TERMINATEDCraiova, Romania
-
Clinica Universidad de Navarra
RECRUITINGPamplona, Spain
Contact
-
HealthPartners Institute - Regions Cancer Care Center,
COMPLETEDSaint Paul, Minnesota, 55101, United States
-
Hm Ciocc Málaga
NOT_YET_RECRUITINGMálaga, Spain
Contact
-
Hospital Puerta de Hierro
RECRUITINGMajadahonda, Spain
Contact
-
Hospital Universitari Dexeus
RECRUITINGBarcelona, Spain
Contact
-
Hospital Universitari Vall D´Hebron
RECRUITINGBarcelona, Spain
Contact
-
Hospital Virgen de la Macarena
RECRUITINGSeville, Spain
Contact
-
Institut Català d'Oncologia Hospital Duran i Reynals
RECRUITINGBarcelona, Spain
Contact
-
Institutul Oncologic "Prof. Dr. Ion Chiricuta"
RECRUITINGCluj-Napoca, Romania
Contact
-
Instytut Centrum Zdrowia Matki Polki
TERMINATEDLodz, Poland
-
Israel-Georgian Medical Research Clinic Helsicore
TERMINATEDTbilisi, Georgia
-
Jerarsi Clinic
RECRUITINGTbilisi, Georgia
Contact
-
Karolinska University Hospital, Solna
RECRUITINGStockholm, Sweden
Contact
-
LTD High Technology Hospital Med Center
RECRUITINGBatumi, Georgia
Contact
-
Lund University Hospital
RECRUITINGLund, Sweden
Contact
-
Maria Skłodowska-Curie National Institute of Oncology
TERMINATEDGliwice, Poland
-
Medical University of Silesia
RECRUITINGKatowice, Poland
Contact
-
Medizinische Hochschule Hannover
RECRUITINGHanover, Germany
Contact
-
NEXT Oncology
COMPLETEDSan Antonio, Texas, 78229, United States
-
Nationales Centrum für Tumorerkrankungen
RECRUITINGHeidelberg, Germany
Contact
-
Oklahoma University , Stephenson Cancer Center
COMPLETEDOklahoma City, Oklahoma, 73104, United States
-
Sahlgrenska University Hospital
COMPLETEDGothenburg, Sweden
-
Sarah Cannon Research Institute
COMPLETEDDenver, Colorado, 80218, United States
-
University of California Los Angeles
RECRUITINGLos Angeles, California, 90024, United States
Contact
-
Universität des Saarlandes
RECRUITINGHomburg, Germany
Contact